Ad
related to: converting from warfarin to apixaban for stroke treatment video- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
- Telestroke Network
Sharing stroke expertise
throughout the state
- Stroke Rehabilitation
Individualized plans
tailored to your needs
- Stroke Risk Factors
Health conditions that
increase your stroke risk
- Learn B.E.F.A.S.T.
Recognize these signs
and symptoms of a stroke
- Telestroke Network
Search results
Results from the WOW.Com Content Network
The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]
"These findings suggest that, due to the consistent benefit of apixaban versus warfarin, current risk-scoring systems for selecting anticoagulation therapy may be less relevant when using apixaban ...
U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...
It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting due to atherosclerosis. Rivaroxaban was the first FXa inhibitor on the market and then followed by apixaban, edoxaban and betrixaban.
Compared to warfarin it has fewer interactions with other medications. [13] It is a direct factor Xa inhibitor. [9] In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. [14] Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.
Artivion Inc (NYSE: AORT) has stopped the PROACT Xa trial to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.
For premium support please call: 800-290-4726 more ways to reach us
/ In atrial fibrillation patients who temporarily or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban or warfarin. An increased risk of stroke and non-CNS embolism was observed in rivaroxaban-treated patients compared with warfarin-treated patients after the end of the study ...
Ad
related to: converting from warfarin to apixaban for stroke treatment video- 262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
